A rare tumour with no drug of its own. NICE has just recommended one
What happened
On 14 October 2026, the National Institute for Health and Care Excellence (NICE) published guidance recommending a drug called nirogacestat, sold as Ogsiveo, for adults with desmoid tumours. The recommendation, published as technology appraisal TA1199, covers adults whose desmoid tumours are progressing and who need systemic treatment. "Systemic" simply means a treatment that travels through the whole body, such as a tablet, rather than one aimed at a single spot. Desmoid tumours are rare growths in the body's soft tissue. Until now, there has been no drug licensed and recommended specifically for them in England and Wales. Trade press covering the decision described it as the first systemic therapy for desmoid tumours to be backed by NICE. The anticipated list price is £15,189.04 for a pack of 56 tablets at 150mg. The company has agreed what NICE calls a simple discount patient access scheme, which means the NHS pays less than the list price. The exact figure is confidential, and NHS organisations get the details through the Commercial Access and Pricing portal. The charity Sarcoma UK welcomed the decision, describing it as a breakthrough for people living with desmoids.
Why this matters
When a condition is rare, it can sit in an awkward gap. There are not many patients, so there is less research, fewer trials and less commercial interest. People can end up being treated with medicines borrowed from other conditions, because nothing has been developed and approved for theirs. That is the gap this decision starts to close. A NICE recommendation is not just a medical opinion. It changes what the NHS has to do. When NICE recommends a treatment in a technology appraisal, NHS organisations in England are normally required to make funding available for it. So a recommendation is the difference between a drug existing and a drug being reachable. For patients and families, it also changes the conversation with a specialist. Instead of asking whether anything is available, the question becomes whether this particular option is right for them. It is worth being honest about scale. Desmoid tumours affect a small number of people. This is not a headline that touches most families. But for those it does touch, it matters a great deal, and it is the kind of decision that rarely gets much attention precisely because the numbers are small.
What the evidence actually says
The recommendation rests mainly on a phase 3 trial called DeFi, which compared nirogacestat with a placebo. Two figures from that trial have been widely reported. The drug improved progression-free survival, which means the length of time before the tumour grew again or the patient's condition got worse. And the objective response rate, which measures the proportion of patients whose tumours shrank by a meaningful amount, was 41% with nirogacestat compared with 8% with placebo. A 41% response rate is a real result. It is also worth reading carefully. It means that most people in the trial did not have a measurable shrinkage of their tumour, even on the drug. Progression-free survival and response rate are not the same thing as a cure, and they are not the same thing as living longer. That is not a criticism of the decision. It is how medicines for rare, slow-growing conditions are usually assessed. NICE weighed the benefit against the cost and the alternatives and concluded it was worth recommending. Two things to keep in mind. First, the recommendation is specifically for adults whose tumours are progressing and who need systemic treatment. It is not for everyone with a desmoid tumour. Many desmoid tumours are watched rather than treated straight away, and that approach has not been replaced. Second, we have reported the trial figures as the published coverage of the NICE decision reports them. If you or someone close to you is affected, the people who can tell you what these numbers mean for your situation are your specialist team, not an article.
Practical advice
If you or a family member has a desmoid tumour: - Ask your specialist team directly whether this recommendation applies to you. The guidance is for adults with progressing tumours who need systemic treatment, and your team will know where you sit. - Ask what the alternatives are, including watching and waiting, and what the trade-offs look like. - Ask about side effects. Every systemic treatment has them, and they are part of the decision, not an afterthought. - Write your questions down before the appointment. It is very easy to forget them in the room. If you want to read the guidance yourself: - NICE publishes its technology appraisals in full and free of charge on its website. TA1199 is the reference for this one. - There is usually a plain-language section aimed at patients and carers. It is worth starting there. If you are supporting someone: - Sarcoma UK and similar charities offer information and support lines for rare soft tissue conditions. Rare conditions can feel isolating, and talking to people who know the territory helps. A note on timing. NICE guidance and the paperwork that puts it into practice do not always move at the same speed. If a treatment has been recommended but is not yet available where you are, ask your team what the local position is rather than assuming it has been refused.
What to know
NICE published guidance on 14 October 2026 recommending nirogacestat (Ogsiveo) for adults with progressing desmoid tumours who need systemic treatment. It is the first systemic therapy NICE has backed specifically for this rare soft tissue condition. The evidence comes largely from the phase 3 DeFi trial, which reported improved progression-free survival and an objective response rate of 41%, compared with 8% on placebo. The anticipated list price is £15,189.04 per 56-tablet pack, with a confidential discount agreed with the NHS. A NICE recommendation normally means NHS funding has to be made available. If this affects you, the recommendation is a reason to have a conversation with your specialist team, not a reason to change anything on your own. Sources: National Institute for Health and Care Excellence, "Nirogacestat for treating desmoid tumours" (TA1199), 14 October 2026, https://www.nice.org.uk/guidance/TA1199; PharmaTimes, "NICE backs first systemic therapy for desmoid tumours", accessed 19 October 2026, https://pharmatimes.com/news/nice-backs-first-systemic-therapy-for-desmoid-tumours/; PMLiVE, "Ogsiveo recommended by NICE to treat rare soft tissue tumours", accessed 19 October 2026, https://pmlive.com/pharma_news/ogsiveo-recommended-by-nice-to-treat-rare-soft-tissue-tumours; Sarcoma UK, "Desmoids breakthrough after new drug is approved", accessed 19 October 2026, https://sarcoma.org.uk/news/desmoids-breakthrough-after-new-drug-is-approved/. This article is for general information and does not replace advice from a doctor, pharmacist or other qualified healthcare professional. Never start, stop or change a treatment on the basis of a news article.
Related articles
44% of over-75s are active, against 64% of 55 to 74s: the government replies
On 22 October 2026 the government published its formal reply to a report by the House of Commons Health and Social Care Committee. The committee's report is ca…
£9.4 million to move mental health workers into children's social care teams
On 23 October 2026 the government announced a new mental health pilot for children and young people who are supported by children's social care. The pilot is c…
One tablet a day: the UK has licensed a new psoriasis treatment
On 23 October 2026 the Medicines and Healthcare products Regulatory Agency (MHRA) licensed a new medicine for plaque psoriasis. The medicine is called icotroki…